Pact makes case for neoantigen-specific TCRs from patient blood

Preclinical studies from Pact Pharma and UCLA suggest neoantigen-specific T cells in patient blood will be reliable blueprints for the company's personalized, engineered cell therapies. Recruitment is ongoing for a Phase I study of Pact's T cell therapy plus an anti-PD-1 therapy in solid tumors with a range of checkpoint inhibitor sensitivities.

In a

Read the full 539 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE